Document Page: First | Prev | Next | All | Image | This Release | Search
File: 102596_sep96_decls1_0014.txt
Subject: DISEASE RISK ASSESSEMENT PROFILE
Unit: VAR. BUMED
Parent Organization: BUMED
Box ID: BX303811
Folder Title: VARIOUS NAVAL MESSAGES FOLDER 1
Document Number: 7
Folder SEQ #: 2
receive one dose of either OPV or IPV. Cholera immunizations are
not routinely recommended.
Immune Globulin (IG) for Hepatitis A is not routinely
recommended for brief (several days) port visits in urban or
tourist areas. One can minimize exposure to Hepatitis A by
avoiding potentially contaminated water or food. Drinking water
(and beverages with ice) of unknown purity, uncooked or partially
cooked shellfish, and uncooked fruits or vegetables which are not
peeled or prepared by the traveler should be avoided.
Immune globulin (gamma globulin) is recommended, however,
for those whose travel is outside usual tourist routes, those who
may be unavoidably exposed to food or drinking water in settings
of questionable sanitation (ex. certain local hosted parties),
those who will be in contact with local young children in
settings of poor sanitation, and to those who will be in-country
for prolonged periods (several weeks). For such travelers, a
single dose of IG prophylaxis of .02 ml/Kg (approx. two (2) cc
deep intramuscular injection for the average adult) is recom-
mended for travel less than three (3) months. For longer
periods of travel, a different dosage, as well as other unrelated
preventive medicine concerns, must be addressed and can be
provided by NEPMU-7.
6. Malaria
Low to moderate risk. The predominant species in the
foothills and oases is Plasnodium falciparum. P. vivax is the
predominant form in the highlands and P. malariae is also
present. No Chloroquine resistance confirmed. Resistance is
suspected in the Tihama coastal region. Risk exists in all areas
except for Hajja and Sada provinces. Risk exists below 1400
urban areas in affected provinces. Period of
greatest risk is from Sep thru Feb. Chemoprophylaxis with
chloroquine and terminal prophylaxis with chlorocruine/primaquine
are recommended for all personnel on a routine port visit to risk
areas. For visits to risk areas with possible resistance,
contact NEPMU-7. Personal protective measures (such as proper
clothing, DEET, and bed nets) should always be stressed.
NOTE: Primaquine should not be given to persons known to be
G6PD defficient. Individuals who do not receive primaquine
should be counselled that they may experience a delayed case of
relapsing (vivax or ovale) malaria weeks to years after exposure.
All febrile episodes should be reported to a physician, who
should be made aware of the possibility of malaria. In general,
relapsing malaria is easily treated and not life-threatening.
Medical Department personnel should review the laboratory and
clinical diagnosis of malaria, as well as treatment. An adequate
supply of treatment drugs such as Fansidar, Quinine, and/or
Mefloquine should be readily available. A recommended reference
2
Document Page: First | Prev | Next | All | Image | This Release | Search
Document 16 f:/Week-37/BX303811/VARIOUS NAVAL MESSAGES FOLDER 1/disease risk assessement profile:1018961449592
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-37
Box ID = BX303811
Unit = VAR. BUMED
Parent Organization = BUMED
Folder Title = VARIOUS NAVAL MESSAGES FOLDER 1
Folder Seq # = 2
Subject = DISEASE RISK ASSESSEMENT PROFILE
Document Seq # = 7
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 18-OCT-1996